Progress in Treatment of Myocardial Injury in Patients with 2019-nCoV: A Chinese Experience

Authors

  • Shixiong Wei Department of Cardiovascular Surgery, Chinese PLA General Hospital, Beijing, China
  • Lin Zhang Department of Cardiovascular Surgery, Chinese PLA General Hospital, Beijing, China
  • Huimin Cui Department of Cardiovascular Surgery, Chinese PLA General Hospital, Beijing, China
  • Shengli Jiang Department of Cardiovascular Surgery, Chinese PLA General Hospital, Beijing, China

DOI:

https://doi.org/10.1532/hsf.2959

Keywords:

2019-nCoV; Diagnosis; Treatment.

Abstract

Since December 2019, the 2019 novel coronavirus (2019-nCoV) infection began to appear in Hubei Province of China and gradually spread to other provinces and other countries. The virus has the characteristics of strong transmission capacity, diverse clinical manifestations, long incubation period, and latent infection, thus posing a serious threat to human life safety and health. With the increasing number of cases and the continuous enrichment of clinical data, 2019-nCoV–infected patients have received more and more attention regarding myocardial injury related to virus infection besides typical respiratory system manifestations. According to the published data, we summarize the myocardial injury manifestations, characteristics, effects on disease condition, and prognosis of 2019-nCoV–infected patients and discuss the possible injury mechanism, treatment methods, and future research directions.

References

Ashour HM, Elkhatib WF, Rahman MM, et al. 2020. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens 9:186.

Cao Y, Li L, Feng Z, et al. 2020. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov 6:11.

Cascella M, Rajnik M, Cuomo A, et al. 2020. Features, evaluation and treatment coronavirus (COVID-19). In: StatPearls. Treasure Island, FL: StatPearls Publishing.

Chen L, Liu HG, Liu W, et al. 2020. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 43:E005.

Fan HH, Wang LQ, Liu WL, et al. 2020. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J (Engl) 133:1051-1056.

Jin Y, Cai L, Cheng Z, et al. 2020. Novel coronavirus (2019-nCoV) guidelines for rapid diagnosis and treatment of pneumonia infected. PLA Med J 45:1-20.

Ling Y, Xu SB, Lin YX, et al. 2020. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl) 133:1039-1043.

Liu J, Zheng X, Tong Q, et al. 2020. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol doi: 10.1002/jmv.25709.

Liu Z, Xiao X, Wei X, et al. 2020. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 5:491-494.

Peng W, Gan X, Tan Y, et al. 2020. Mechanisms of cardiovascular system damage and treatment progress of infectious diseases in novel coronavirus [J/OL]. Chin J Nosocomiol.

Peng YD, Meng K, Guan HQ, et al. 2020. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 48:E004.

WHO. 2020. Novel coronavirus-China [EB/OL]. http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.

Yang W, Cao Q, Qin L, et al. 2020. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708-1720.

Published

2020-06-15

How to Cite

Wei, S., Zhang, L., Cui, H., & Jiang, S. (2020). Progress in Treatment of Myocardial Injury in Patients with 2019-nCoV: A Chinese Experience. The Heart Surgery Forum, 23(4), E426-E429. https://doi.org/10.1532/hsf.2959

Issue

Section

Articles

Most read articles by the same author(s)

1 2 > >>